SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type-Reference-Cited by-同舟云学术

SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type

Published:2023-08 Issue: Volume: Page:117236
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Bechmann Louise E.,Emanuelsson Frida,Nordestgaard Børge G.,Benn Marianne

Funder

Danmarks Frie Forskningsfond

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range;Bailey;Diabetes Obes. Metabol.,2012

2. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial;Bode;Hosp. Pract.,2013

3. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Häring;Diabetes Care,2013

4. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis;McGuire;JAMA Cardiology,2021

5. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials;Vaduganathan;Lancet (London, England),2022

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients;Journal of Clinical Medicine;2024-08-21

2. Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease;The Egyptian Journal of Internal Medicine;2024-08-13

3. Safety and Efficacy of Remogliflozin in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis;Cureus;2024-08-04

4. Lessons from PROMINENT and prospects for pemafibrate;Cardiovascular Diabetology;2024-07-29

5. Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes;BMC Medicine;2024-07-02